Aurobindo Pharma's Subsidiary CuraTeQ Gets EU Panel Nod For Breast Cancer Biosimilar

Aurobindo Pharma Ltd. has announced that its wholly-owned step-down subsidiary, CuraTeQ Biologics, has received a positive recommendation from the European Medicines Agency's committee for medicinal products to market its drug, Dazublys.

The committee recommended Dazublys at a 150 milligram dosage. This drug which is a biosimilar to Trastuzumab is indicated for the treatment of HER2-positive metastatic and early-stage breast cancer.

This marks the company's third biosimilar in five months to receive a positive recommendation from the committee. Aurobindo Pharma aims to launch 10 biosimilars across oncology and immunology therapy segments by 2030.